The decision was difficult but necessary, according to MaxQ CEO Michael Rosenberg. Algorithms designed to identify a specific clinical problem are only part of a larger solution needed to impact patient outcomes, he said.
Instead of developing AI algorithms that would be considered medical devices and require regulatory approval, MaxQ is now building non-image-based AI algorithms that will go beyond the radiology department to the company, Rosenberg said.
“Our new solution leverages the vast amount of medical data to identify abnormalities that could lead to poor clinical outcomes or inefficiencies in care.” he said AuntMinnie.com. “Stay tuned.”
Due to the change in focus, however, the company’s sales and marketing teams involved in bringing Accipio to market were made redundant.
Designed to help prioritize the clinical evaluation of adult non-contrast cranial computed tomography studies that show indications of ICH, Accipio Ix had received clearance from the United States Food and Drug Administration (FDA) in 2018 The software had received Fast Track designation from the FDA earlier in the year, paving the way for rapid regulatory review under the FDA’s new Breakthrough Devices program.
Later, the vendor offered a suite of Accipio applications – the Accipio Clinical Platform – which included Accipio Ix for ICH triage and reporting, Accipio Ax for slice-level annotation, and Accipio Dxg for triage for the presence and absence of ICH.
MaxQ sold the Accipio software suite primarily through channel partners including Fujifilm Medical Systems USA, Philips Healthcare, GE Healthcare, Arterys, Nuance Communications, Samsung Neurologica, and IBM Watson Health.
“Rest assured, our channel partners have what they need to support their customer base,” Rosenberg said.
The shift in focus marks the latest evolution of the company, which began as MedyMatch Technology, an Israeli AI technology developer. The company then changed its name in 2018 to MaxQ AI to better reflect its focus on AI.
Copyright © 2022 AuntMinnieEurope.com
